The lab published a new paper today in on reprogramming the function of lymph nodes - tissues that coordinate immune function - to promote tolerance and combat tolerance. The study used a unique approach to deposit degradable polymer particles in lymph nodes, promoting regulatory cells that helps control inflammation in diseases such as multiple sclerosis (MS). Working in pre-clinical models of MS, the studies show that a single treatment can permanently reverse paralysis by promoting regulatory cells and reducing immune cell inflammation into the central nervous system.
Congratulations to all the authors on their work! The paper is open access and available online at Cell Reports. The authors are Lisa Tostanoski, Dr. Yu-Chieh Chiu, Joshua Gammon, Dr. Thomas Simon, James Andorko, Dr. Jonathan Bromberg, and Dr. Christopher M. Jewell (corresponding).
Click the link to read the press release.
Congratulations to all the authors on their work! The paper is open access and available online at Cell Reports. The authors are Lisa Tostanoski, Dr. Yu-Chieh Chiu, Joshua Gammon, Dr. Thomas Simon, James Andorko, Dr. Jonathan Bromberg, and Dr. Christopher M. Jewell (corresponding).
Click the link to read the press release.
Caption: Tostanoski et al. use local delivery of polymer depots to program the lymph node environment for tolerance. The cartoon shows T cells learning to become TREG (happy pupils) instead of inflammatory TH1 or TH17 (mischievous pupils) cells owing to the presence of tolerogenic particles. Targeted delivery during autoimmunity promotes systemic, myelin-specific tolerance that restrains inflammatory cells in the central nervous system and reverses paralysis. Concept: Chris Jewell, Rebekah Taylor. Artwork: Kelly Finan.